AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22623316 — intervention group
Group type: COMPARATOR
Intervention: MBSR and AE (compared to untreated group)
Number of subjects: 56
Study 20600255 — intervention group
Group type: EXPERIMENTAL
Intervention: Decided to do (DTD) screening tests
Number of subjects: 1515
Study 20600255 — intervention group
Group type: COMPARATOR
Intervention: Not considering or undecided (NCU) about screening
Number of subjects: 1515
Study 20600255 — intervention group
Group type: COMPARATOR
Intervention: Had never heard of (NHO) screening tests
Number of subjects: 1515
Study 20600255 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1515
Study 20600255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cancer screening
Number of subjects: 1515
Study 20600255 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in screening importance
Number of subjects: 1515
Study 20600255 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 1515
Study 20600255 — intervention group
Group type: COMPARATOR
Intervention: Gender (female)
Number of subjects: 1515
Study 20600255 — intervention group
Group type: COMPARATOR
Intervention: Race (white)
Number of subjects: 1515
Study 17511854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a 30 mug intramuscularly once a week for 3 years
Number of subjects: 217
Study 17511854 — intervention group
Group type: COMPARATOR
Intervention: Placebo intramuscularly once a week for 3 years
Number of subjects: 217
Study 17511854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a
Number of subjects: 217
Study 14725822 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 12
Study 14725822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11068835 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 50
Study 11068835 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 50
Study 9376994 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 57
Study 9376994 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated CD8 T cells (HLA-DR positivity)
Number of subjects: 57
Study 9376994 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels
Number of subjects: 57
Study 9376994 — intervention group
Group type: EXPERIMENTAL
Intervention: %CD8 T cells and serum IL-6 levels
Number of subjects: 57
Study 8404785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) fish oil concentrate (2.2 g EPA, 1.2 g DHA)
Number of subjects: 31
Study 8404785 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride (TG) fish oil concentrate (2.2 g EPA, 1.4 g DHA)
Number of subjects: 31
Study 8404785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8404785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) fish oil concentrate
Number of subjects: 31
Study 8404785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl Ester (EE) and Triglyceride (TG) fish oils
Number of subjects: 31
Study 3701583 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors who were more successful at biasing their clients' expectancies
Number of subjects: 78
Study 3701583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients who were more susceptible to counselor bias
Number of subjects: 78
Study 30966728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg single-dose submucosal betamethasone
Number of subjects: 43
Study 30966728 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 43
Study 28256747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR) 50 mg/100 mg for 12 weeks
Number of subjects: 159
Study 28256747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR)
Number of subjects: 159
Study 28256747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Deferred-Treatment Group)
Number of subjects: 159
Study 25877363 — intervention group
Group type: EXPERIMENTAL
Intervention: High condylectomy with postsurgical orthodontic therapy (group A)
Number of subjects: 40
Study 25877363 — intervention group
Group type: COMPARATOR
Intervention: High condylectomy without postsurgical orthodontic therapy (group B)
Number of subjects: 40
Study 24165906 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium solution 5 µg
Number of subjects: 154
Study 24165906 — intervention group
Group type: COMPARATOR
Intervention: Powder 18 µg
Number of subjects: 154
Study 24165906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 22629311 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (OF) diet
Number of subjects: 21
Study 22629311 — intervention group
Group type: COMPARATOR
Intervention: Weight maintaining (WM) diet
Number of subjects: 21
Study 22629311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time during OF
Number of subjects: 21
Study 19565742 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 19565742 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (placebo acupuncture)
Number of subjects: 0
Study 17674637 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention group (n = 165)
Number of subjects: 507
Study 17674637 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention group (n = 176)
Number of subjects: 507
Study 17674637 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group (n = 166)
Number of subjects: 507
Study 17674637 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention group (women)
Number of subjects: 507
Study 17674637 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention group (women)
Number of subjects: 507
Study 17674637 — intervention group
Group type: COMPARATOR
Intervention: Control group (women)
Number of subjects: 507
Study 15464496 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 15464496 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during CPB
Number of subjects: 40
Study 15464496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leukocyte filtration)
Number of subjects: 40
Study 10722499 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (2 mg/kg of body weight)
Number of subjects: 19
Study 9197354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg p.o. t.i.d.
Number of subjects: 29
Study 9197354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1491608 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil‐supplemented formula
Number of subjects: 65
Study 1491608 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 65
Study 3988972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg
Number of subjects: 34
Study 3988972 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 34
Study 3988972 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 34
Study 30240980 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 94
Study 30240980 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 94
Study 28639467 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine diluted from a concentrate for solution for infusion (CSI) containing ethanol
Number of subjects: 24
Study 28639467 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized powder without ethanol (control)
Number of subjects: 24
Study 27233237 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention (an 18‐week program with health knowledge and skills embedded in language, literacy, and numeracy training)
Number of subjects: 300
Study 27233237 — intervention group
Group type: COMPARATOR
Intervention: Standard Language Literacy and Numeracy (LLN) program (usual LLN classes, specifically excluding health content)
Number of subjects: 300
Study 27233237 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy intervention
Number of subjects: 300
Study 27233237 — intervention group
Group type: COMPARATOR
Intervention: Standard Language Literacy and Numeracy (LLN) program
Number of subjects: 300
Study 25427568 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program including rehabilitative therapy, intake of hyperproteic nutritional shakes, memory workshop, and medication review.
Number of subjects: 352
Study 25427568 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving recommendations on nutrition, healthy lifestyles, and home risks.
Number of subjects: 352
Study 23609385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy (10 to 80 mg daily for up to 14 weeks)
Number of subjects: 166
Study 20465435 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol chocolate (5 to 15 g)
Number of subjects: 0
Study 20465435 — intervention group
Group type: COMPARATOR
Intervention: Sucrose chocolate (placebo)
Number of subjects: 0
Study 18469202 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT)
Number of subjects: 382
Study 18469202 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral Adipose Tissue (VAT) after addition of HOMA-IR
Number of subjects: 382
Study 18469202 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI) and Subcutaneous Adipose Tissue (SAT)
Number of subjects: 382
Study 16614984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 300 mL saline (16.7%)
Number of subjects: 8
Study 16614984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 600 mL saline (8.3%)
Number of subjects: 8
Study 16614984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of 50 g of glucose in 1200 mL saline (4.1%)
Number of subjects: 8
Study 16614984 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%) infusion after glucose infusion
Number of subjects: 8
Study 12595910 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 0
Study 12595910 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10946333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded allograft and homograft restorations
Number of subjects: 20
Study 8635376 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol, 50 microg twice a day for seven doses
Number of subjects: 8
Study 8635376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1442650 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental reduced-protein formula (13 g/L protein, whey-casein ratio 40:60, added tryptophan 490 mumol/L)
Number of subjects: 95
Study 1442650 — intervention group
Group type: COMPARATOR
Intervention: Conventional formula (15 g protein/L, whey-casein ratio 60:40)
Number of subjects: 95
Study 1442650 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 95
Study 31691413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity internet intervention (n=72)
Number of subjects: 166
Study 31691413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity internet intervention (n=71)
Number of subjects: 166
Study 31691413 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (n=23)
Number of subjects: 166
Study 30562195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track radioiodine ablative therapy (RIT) 1 week after thyroidectomy
Number of subjects: 20
Study 30562195 — intervention group
Group type: COMPARATOR
Intervention: Standard care (RIT planned 4 to 6 weeks after surgery)
Number of subjects: 20
Study 27837950 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular congenital heart disease (CHD) infants
Number of subjects: 48
Study 27837950 — intervention group
Group type: COMPARATOR
Intervention: Healthy control infants
Number of subjects: 48
Study 26537053 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg oral once daily)
Number of subjects: 42
Study 26537053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to raloxifene)
Number of subjects: 42
Study 26537053 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 42
Study 26537053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23524843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sensory and motor stimulation program (16 sessions in rehabilitation center, daily sessions at home for 8 weeks)
Number of subjects: 21
Study 23524843 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (control group)
Number of subjects: 21
Study 23524843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive sensory and motor stimulation program
Number of subjects: 21
Study 22114905 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch (FT)
Number of subjects: 300
Study 20028261 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%/Timolol 0.5%
Number of subjects: 60
Study 20028261 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/Timolol
Number of subjects: 60
Study 20028261 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine plus Dorzolamide/Timolol
Number of subjects: 60
Study 17661193 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 17661193 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 16234518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex)
Number of subjects: 9366
Study 16234518 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 9366
Study 11865387 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial traction of the cervical spine after extubation
Number of subjects: 30
Study 11865387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no axial traction)
Number of subjects: 30
Study 10077966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethisorp patches
Number of subjects: 12
Study 10077966 — intervention group
Group type: COMPARATOR
Intervention: Lyodura
Number of subjects: 12
Study 10077966 — intervention group
Group type: COMPARATOR
Intervention: Syspurderm
Number of subjects: 12
Study 10077966 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 12
Study 7594125 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet
Number of subjects: 840
Study 7594125 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 840
Study 7594125 — intervention group
Group type: COMPARATOR
Intervention: Very-low-protein diet
Number of subjects: 840
Study 7594125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring and dietitian support
Number of subjects: 840
Study 2149510 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus tamoxifen
Number of subjects: 0
Study 2149510 — intervention group
Group type: COMPARATOR
Intervention: Zoladex alone
Number of subjects: 0
Study 86845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital A (operated upon 66 out of 206 patients, 32%)
Number of subjects: 302
Study 86845 — intervention group
Group type: COMPARATOR
Intervention: Hospital B (operated upon 44 out of 96 patients, 46%)
Number of subjects: 302
Study 31983598 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum group (TENS therapy)
Number of subjects: 151
Study 31983598 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 151
Study 31845167 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 164
Study 31216880 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 63
Study 31216880 — intervention group
Group type: COMPARATOR
Intervention: Standard information program (control)
Number of subjects: 63
Study 31216880 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training (per-protocol analysis)
Number of subjects: 63
Study 27076283 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% one repetition maximum (1RM) with blood flow restriction (BFR)
Number of subjects: 40
Study 27076283 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% one repetition maximum (1RM) with blood flow restriction (BFR)
Number of subjects: 40
Study 27076283 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% one repetition maximum (1RM)
Number of subjects: 40
Study 27076283 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% and 30% to failure
Number of subjects: 40
Study 23941781 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐focused attention and safety behaviours experiment
Number of subjects: 32
Study 23941781 — intervention group
Group type: EXPERIMENTAL
Intervention: individual cognitive therapy (CT)
Number of subjects: 32
Study 23941781 — intervention group
Group type: COMPARATOR
Intervention: interpersonal therapy (IPT)
Number of subjects: 32
Study 22547421 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (initiate ART immediately)
Number of subjects: 4000
Study 22547421 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART (defer treatment until CD4 count <350 cells/µL)
Number of subjects: 4000
Study 21276222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Light Treatment (SLT) at 10,000 lux for 30 minutes
Number of subjects: 22
Study 21276222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity Blue-enriched Light Treatment (BLT) at 750 lux for 30 minutes
Number of subjects: 22
Study 21276222 — intervention group
Group type: COMPARATOR
Intervention: Both SLT and BLT
Number of subjects: 22
Study 19290010 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention promoting low-fat dairy products and whole-grain bread, eliminating sweets and sweetened drinks, increasing physical activity by 30 min/day during school time
Number of subjects: 3135
Study 19290010 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 3135
Study 19290010 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 3135
Study 19290010 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3135
Study 17132082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hue scaling technique under five different illuminations
Number of subjects: 0
Study 17132082 — intervention group
Group type: COMPARATOR
Intervention: Blocked control experiment with test surfaces from one illumination condition
Number of subjects: 0
Study 17132082 — intervention group
Group type: COMPARATOR
Intervention: Randomized order control experiment
Number of subjects: 0
Study 14720270 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur (BB) 25 mg
Number of subjects: 16
Study 14720270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 11247897 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS)
Number of subjects: 6394
Study 11247897 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) combined with faecal occult blood testing
Number of subjects: 6394
Study 9118762 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B
Number of subjects: 71
Study 9118762 — intervention group
Group type: COMPARATOR
Intervention: Engerix B
Number of subjects: 71
Study 8505831 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 2000 mL of 5% glucose in water or saline plus 1000 mL of 5% amino acid solution per day (approximately 10 kcal/kg per day and 1 g of protein per kilogram per day)
Number of subjects: 42
Study 8505831 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 2000 mL of 5% glucose in water or saline plus 500 mL of 5% amino acid solution and 500 mL of 10% fat emulsion (approximately 20 kcal/kg per day and 0.5 g of protein per kilogram per day)
Number of subjects: 42
Study 8505831 — intervention group
Group type: COMPARATOR
Intervention: Group A: 3000 mL of a 5% glucose in water or glucose in saline infusion per day (approximately 10 kcal/kg per day)
Number of subjects: 42
Study 3318754 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 80
Study 3318754 — intervention group
Group type: COMPARATOR
Intervention: Individual supportive therapy
Number of subjects: 80
Study 29883964 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h)
Number of subjects: 40
Study 29883964 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 40
Study 27406781 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment group (n=14)
Number of subjects: 27
Study 27406781 — intervention group
Group type: COMPARATOR
Intervention: Information group (n=13)
Number of subjects: 27
Study 25138332 — intervention group
Group type: EXPERIMENTAL
Intervention: True oximetry measurements
Number of subjects: 213
Study 25138332 — intervention group
Group type: COMPARATOR
Intervention: Altered oximetry measurements (3 percentage points above true values)
Number of subjects: 213
Study 23092146 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide bleaching gel (Opalescence PF 20)
Number of subjects: 0
Study 23092146 — intervention group
Group type: COMPARATOR
Intervention: Control specimens stored in water (one‐day and two‐month)
Number of subjects: 0
Study 19904246 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20-40 mg daily
Number of subjects: 514
Study 19904246 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 514
Study 19904246 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Esomeprazole and LARS)
Number of subjects: 514
Study 18048059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 10 ml
Number of subjects: 41
Study 18048059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 30 ml
Number of subjects: 41
Study 18048059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 41
Study 15624072 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN patients receiving RCT study medication
Number of subjects: 0
Study 15624072 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN patients with schizophrenia
Number of subjects: 0
Study 15624072 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN patients with bipolar I disorder
Number of subjects: 0